Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Oncology Drugs - Benelux

Benelux
  • The projected revenue in the Oncology Drugs market in Benelux is estimated to reach US$2.07bn in 2024.
  • It is expected to experience an annual growth rate (CAGR 2024-2029) of 6.50%, leading to a market volume of US$2.83bn by 2029.
  • In comparison to other countries, United States is anticipated to generate the highest revenue, amounting to US$103.90bn in 2024.
  • The Benelux region is witnessing a surge in the development and adoption of innovative oncology drugs, positioning it as a leading hub for cancer research and treatment in Europe.

Definition:
The Oncology Drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

In-Scope

  • Treatment for different types of cancer, including skin cancer, leukemia, lymphoma, and multiple myeloma
  • Chemotherapeutic agents
  • Immuno-oncology drugs
  • Oncology orphan drugs

Out-Of-Scope

  • Radiation therapy
  • Medical devices
Oncology Drugs: market data & analysis - Cover

Market Insights report

Oncology Drugs: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Analyst Opinion

    The Oncology Drugs market in Benelux has been experiencing steady growth in recent years, driven by several key factors.

    Customer preferences:
    Patients in Benelux are increasingly seeking personalized treatment options for their cancer, leading to a rise in demand for targeted therapies. Additionally, there is a growing awareness of the benefits of early cancer detection, leading to an increase in demand for screening and diagnostic tools.

    Trends in the market:
    One major trend in the Oncology Drugs market in Benelux is the increasing use of immunotherapy, which harnesses the body's own immune system to fight cancer. This approach has shown promising results in treating certain types of cancer and is expected to continue to gain traction in the region. Another trend is the growing importance of biosimilars, which are lower-cost versions of biologic drugs. As patents for many biologics expire, biosimilars are expected to become increasingly prevalent in the market.

    Local special circumstances:
    Benelux countries have a strong tradition of universal healthcare coverage, which means that the cost of cancer treatment is largely covered by the government. This has helped to ensure that patients have access to the latest treatments, regardless of their ability to pay. However, this also means that healthcare budgets are under pressure, leading to a focus on cost containment measures.

    Underlying macroeconomic factors:
    The overall economic growth in Benelux has been steady, which has supported the growth of the Oncology Drugs market. However, there are concerns about the impact of Brexit on the region, particularly in terms of trade and investment. Additionally, the aging population in Benelux is expected to increase the incidence of cancer in the coming years, which will further drive demand for Oncology Drugs.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Oncology Drugs: market data & analysis - BackgroundOncology Drugs: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Cancer worldwide - Statistics & Facts

    Cancer is one of the leading causes of death worldwide, with lung cancer alone ranked the sixth leading cause of death in 2021. Cancer, also known as malignant tumors and neoplasms, is the result of interactions between personal genetic factors and external agents causing abnormal transformations of cells into tumors over time. As the global population has increased in age, the incidence of new cancer cases has also risen, contributing to a higher number of deaths each year. In 2022, nearly 10 million deaths were caused by cancer worldwide- a number which is expected to reach over 15 million by 2040.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.